Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

It lowers blood pressure and cholesterol and  sends 'fullness' signals to the brain, like a weight-loss drug. Here are simple ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker ...